Aldeyra The

For the year ended December 31, 2022, Aldeyra reported a net loss of $62.0 million, or $1.06 per share, versus a net loss of $57.8 million, or $1.07 per share in 2021. Research and development expense was $47.3 million, up from $44.9 million; general and administrative expense was $15.4 million, up from $11.3 million; and total operating expenses were $62.7 million, versus $56.2 million a year earlier. Cash, cash equivalents and marketable securities were $174.3 million as of December 31, 2022. Management said that cash is expected to fund currently projected operating expenses into the second half of 2024, including initial commercialization and launch plans for Reproxalap and ADX-2191 if approved, and ongoing development. Bruce Greenberg added that the forecast is conservative and does not include any revenue or any revenue from a license arrangement.

Todd Brady framed 2022 as a transformational year marked by two FDA-accepted NDAs and said those filings validate Aldeyra’s platforms in immune-mediated ocular and systemic disease. He repeatedly emphasized the company’s RASP-modulation strategy as a differentiated, broad anti-inflammatory approach intended to avoid the toxicity of single-protein targeting. His tone was confident and optimistic, especially around Reproxalap’s breadth of activity, ADX-2191’s potential first-to-market position in ocular lymphoma, and the upcoming expansion of the pipeline with ADX-246 and ADX-248.

Bruce Greenberg focused on liquidity and the year-end financials. He said Aldeyra had $174.3 million in cash, cash equivalents and marketable securities at December 31, 2022, and that this should cover projected operating expenses into the second half of 2024, even with launch plans for Reproxalap and ADX-2191. He also gave the annual loss figures: $62.0 million net loss, or $1.06 per share, with R&D at $47.3 million and G&A at $15.4 million; he noted the cash forecast is conservative and excludes revenue and license-arrangement revenue.

Analysts focused on Reproxalap partnering, potential commercialization timing, and whether a second dry-eye filing in allergic conjunctivitis will be needed. Brady said partnering discussions are “robust” and involve multiple parties, and he expects partners would want to be involved before label negotiations, which he placed in the September-to-October timeframe. On allergic conjunctivitis, he said the key goal is to show activity in INVIGORATE-2 first, then decide whether an NDA is needed. Questions also covered ADX-246’s positioning, with Brady saying it is more potent than ADX-629 and may support once-daily dosing, and that it may inherit some of ADX-629’s indications if the earlier program shows activity. On commercialization, he said ADX-2191 will likely be more of a targeted market-access effort given the small physician population, while Reproxalap may be launched internally if partnering does not come together.